TScan Therapeutics (TCRX) Set to Release Earnings on Wednesday

TScan Therapeutics (NASDAQ:TCRX) is projected to announce its Q3 2026 results before the market opens on Wednesday, November 11th. Analysts expect TScan Therapeutics to announce earnings of ($0.18) per share and revenue of $0.46 million for the quarter. Investors may visit the company’s upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Wednesday, November 11, 2026 at 9:30 AM ET.

TScan Therapeutics (NASDAQ:TCRX) last announced its quarterly earnings data on Wednesday, August 12th. The company reported ($0.23) EPS for the quarter, beating analysts’ consensus estimates of ($0.25) by $0.02. TScan Therapeutics had a negative return on equity of 108.72% and a negative net margin of 1,655.35%. The company had revenue of $1.05 million during the quarter, compared to the consensus estimate of $1.88 million. On average, analysts expect TScan Therapeutics to post ($0.79) EPS for the current fiscal year and ($0.65) EPS for the next fiscal year.

TScan Therapeutics Trading Up 4.2%

Shares of NASDAQ TCRX opened at $0.20 on Wednesday. The business has a fifty day simple moving average of $0.33 and a 200-day simple moving average of $0.84. The company has a quick ratio of 3.37, a current ratio of 3.37 and a debt-to-equity ratio of 0.31. The company has a market cap of $13.35 million, a price-to-earnings ratio of -0.20 and a beta of 1.21. TScan Therapeutics has a 12 month low of $0.17 and a 12 month high of $1.47.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on the stock. Weiss Ratings downgraded shares of TScan Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, September 8th. HC Wainwright lowered TScan Therapeutics from a “buy” rating to a “neutral” rating and set a $1.00 target price for the company. in a report on Tuesday, September 8th. Lifesci Capital cut TScan Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, September 2nd. Benchmark reiterated a “buy” rating on shares of TScan Therapeutics in a report on Thursday, August 13th. Finally, Wedbush lowered TScan Therapeutics from a “buy” rating to a “neutral” rating and set a $1.00 price target on the stock. in a research report on Wednesday, September 2nd. Two analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $2.67.

TScan Therapeutics Company Profile

TScan Therapeutics, Inc is a clinical-stage biotechnology company developing T cell receptor-engineered T cell (TCR-T) therapies for cancer. Its approach involves genetically modifying a patient’s T cells to recognize specific cancer-related antigens, with the goal of directing the immune system to attack malignant cells.

The company’s pipeline includes investigational therapies for hematologic malignancies and solid tumors. Its lead programs, TSC-100 and TSC-101, are designed to target the HA-1 antigen in patients with certain blood cancers following an allogeneic hematopoietic stem cell transplant.